Across TCGA pan-cancer cohorts, TRIM13 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TRIM13 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TRIM13 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TRIM13 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where TRIM13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.891	0.404	.009	10	view →
PDAC	DFS	Median	II,III,IV	0.590	0.895	.009	7	view →
GBM	DFS	Quartile	All	0.529	0.761	.038	3	view →
LSCC	DFS	Median	All	0.813	0.599	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: TRIM13 tumor-vs-normal RNA expression · all TRIM13 data types